Assessment of Ki67 immunohistochemical expression as a prognostic marker in breast carcinoma

Cervical Carcinoma: Oncobiology and Biomarkers

“…HPV DNA, E6/E7 mRNA p53, Rb, p16INK4a, telomerase RNA gene (TERC), serum SCC-Ag, OCVA1 [8,[10][11][12][13]15,[20][21][22][23][24][25][26] Markers of cell cycle and proliferation Ki-67, cyclin D1, p53, p63 [12,[26][27][28][29][30][31][32][33][34][35][36] Markers of apoptosis P53, BCL-2, BCL-XL, BAX [10,27,[37][38][39][40][41][42][43][44] Expression of cytokeratins-markers of differentiation CK7, CK8, CK17, CK19 [27,36,37,[45][46][47][48][49] Markers of cell adhesion, invasion and metastasis E-cadherin, P-cadherin, CD44, ADAM9, MT1-MMP, TIMP-1, TIMP-2, MT1-MMP, MMP-2, MMP-1, MMP-9, MMP-14, proMMP-14 furin, gelatinase, TIMP-1 and TIMP-2 [27,[50][51][52]…”

“…Ki-67/MIB1 is considered to be a prognostic marker of cervical cancer [29]; however, other features of the disease, such as the degree of malignancy, damage to the lymph nodes, and metastasis, may influence patient survival [28,33]. It should be noted that despite the fact that it is well-known that Ki-67/MIB-1 is present in the nuclei of cells in the G1, S, G2, and mitotic phases, nevertheless, the mechanism of expression of the Ki-67 gene is still unknown [33], and for an accurate quantitative assessment of the degree of expression of the Ki-67 marker, a comparative analysis of the results obtained in various studies, unified methods for calculating expression indicators are required, possibly with the use of digital microscopy methods [30,34].…”